LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 1401 | 4499 | 4139 | 1.0870 | 1.1097 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 1401 | 4163 | 4095 | 1.0165 | 1.0213 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 1401 | 4634 | 4272 | 1.0846 | 1.1037 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 1 | H05 | 72 | hr | 1401 | 4092 | 4139 | 0.9886 | 0.9854 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 2 | H05 | 72 | hr | 1401 | 3933 | 4095 | 0.9604 | 0.9484 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 3 | H05 | 72 | hr | 1401 | 4139 | 4272 | 0.9688 | 0.9610 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 1 | H04 | 72 | hr | 1401 | 3753 | 4139 | 0.9067 | 0.8785 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 2 | H04 | 72 | hr | 1401 | 4151 | 4095 | 1.0136 | 1.0175 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 3 | H04 | 72 | hr | 1401 | 3851 | 4272 | 0.9014 | 0.8749 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 1401 | 3596 | 4139 | 0.8688 | 0.8278 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 1401 | 3413 | 4095 | 0.8334 | 0.7777 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 1401 | 3907 | 4272 | 0.9145 | 0.8919 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 1401 | 3370 | 4139 | 0.8142 | 0.7535 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 1401 | 3285 | 4095 | 0.8021 | 0.7343 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 1401 | 3184 | 4272 | 0.7453 | 0.6658 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 1 | H01 | 72 | hr | 1401 | 1483 | 4139 | 0.3583 | 0.0368 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 2 | H01 | 72 | hr | 1401 | 1176 | 4095 | 0.2872 | -0.1072 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 3 | H01 | 72 | hr | 1401 | 1392 | 4272 | 0.3258 | -0.0042 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 1 | H12 | 72 | hr | 1401 | 4342 | 3978 | 1.0913 | 1.1196 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 2 | H12 | 72 | hr | 1401 | 4743 | 4213 | 1.1257 | 1.1549 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 3 | H12 | 72 | hr | 1401 | 4777 | 4545 | 1.0508 | 1.0593 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 1 | H11 | 72 | hr | 1401 | 4026 | 3978 | 1.0119 | 1.0158 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 2 | H11 | 72 | hr | 1401 | 4395 | 4213 | 1.0431 | 1.0539 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 3 | H11 | 72 | hr | 1401 | 4806 | 4545 | 1.0572 | 1.0666 |
| SK-BR-3 | Foretinib | 0.37 | uM | LJP5 | 1 | H10 | 72 | hr | 1401 | 1674 | 3978 | 0.4208 | 0.1253 |